Research

  • Presence hallucinations early sign of Parkinson’s say scientists

    So-called 'presence hallucinations' where you have the strong feeling someone is standing behind you when they're not, may be an early sign of Parkinson's disease. Scientists say the feeling is a common pointer to the progressive brain disorder that affects the nervous system. But often patients and clinicians dismiss the hallucinations as a side effect [...]

  • Women taking HRT may be at greater risk of dementia

    Women taking hormone replacement therapy (HRT) to relieve menopausal symptoms may be at greater risk of developing dementia and Alzheimer's disease, a new study suggests. The research conducted in Denmark involving more than 60,000 women and published in the latest issue of The British Medical Journal, showed that those using HRT treatments - which include [...]

  • Alzheimer’s patients perceive pain differently, new study finds

    Alzheimer's disease patients may not feel pain in the same way as other people, a new study has suggested. The research from King's College London says this is due to the lack of a protein called TLR4 in the central nervous system. The team behind the investigation said the finding could open the way to [...]

  • Study deepens understanding of treatment-resistant hypertension

    A new study conducted in the United States has identified a medication that could bring treatment-resistant hypertension under control. Elevated blood pressure affects more than one billion adults worldwide. Its prevalence increases with age with more than 60% of adults over the age of 65 diagnosed with the condition, which can lead to stroke or [...]

  • Global consortium to work on AI-powered personalised care for heart failure

    Heart failure affects more than 64 million people worldwide and is the main cause of hospitalisation in those over 65. With the global prevalence of the condition predicted to increase by almost 50% by the end of this decade, Amsterdam UMC is launching a consortium to look for an AI-powered solution. The group "has the [...]

  • New combination therapy shows promising results for prostate cancer

    A novel combination prostate cancer therapy has been approved by the US Food and Drug Administration. The new treatment combines two Pfizer-produced cancer drugs, Xtandi (also known as enzalutamide) and Talzenna (which also goes under the name talazoparib). While Xtandi is a medication typically used for prostate cancer, the addition of Talzenna - an oral [...]

  • Alzheimer’s expert on bridging the gap between ‘bench’ research and the community

    "Imagine it’s construction season in Michigan. Normally, it might take you 10 to 15 minutes to get from point A to point B. "But when there is construction, it slows you down, now taking 15 to 20 minutes. And if the highway is closed, it might take you even longer." Irving Vega is describing what [...]

  • Exercise may trigger stroke in people with blocked arteries

    Regular exercise is good for us. Or so we keep being told. We know that being physically active helps manage weight, strengthens bones and muscles, keeps the brain active, improves mental health and mood, and reduces the risk of developing certain diseases. However, it seems that in some cases, exercise could actually be detrimental to [...]

  • Vitamin supplements shown to improve nutrition biomarkers in older men

    A six-month study of healthy older men is the latest to support the positive benefits of taking multivitamin and multimineral supplements on key nutrition biomarkers. The research led by Oregon State University's Tory Hagen and Alexander Michels has also shown that the changes in nutrition status could have direct connections to cellular function, measured by the [...]

  • AstraZeneca enters cholesterol drug delivery collaboration with biotech start-up

    Multinational pharmaceutical company AstraZeneca has teamed up with 'young' Chinese biotech Cholesgen to develop new drugs to target high cholesterol and related metabolic diseases. The three-year collaboration will see Shanghai-based Cholesgen receive an initial payment and a pre-defined license package for each qualified drug candidate nominated by UK-headquartered AstraZeneca to progress into clinical development. The [...]